ABUS.US Arbutus Biopharma Corp

Healthcare Biotechnology USA Stocks
4.09 USD
Close of Nov 13, 2026
3.50 5.45
Market cap
USD 627M
P/E
3.7x
P/B
6.95x
ROE
347.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ABUS.US undervalued?

Graham number
Price4.09
Graham value3.85
Premium6.2%

ABUS.US trades 6.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arbutus Biopharma Corp fundamental analysis

No fundamental analysis for Arbutus Biopharma Corp yet.

Arbutus Biopharma Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has …

Full company profile